Chemotherapy for tuberculosis; yesterday, today, and tomorrow (basic and clinical studies)

Kekkaku

Volumn 73, Issue 7, 1998, Pages 459-476

  Aoyagi, Teruo ^a  

^a Higashisaitama National Hospital   (Japan)

Author keywords

Biological response modifier; Controlled clinical trial; MDR TB (multi drug resistant tuberculosis); Pharmacokinetics of INH; Short course chemotherapy

Indexed keywords

ISONIAZID; PASINIAZID; PYRAZINAMIDE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; CROSS RESISTANCE; HUMAN; JAPAN; MULTIDRUG RESISTANCE; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CONTROLLED CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FORECASTING; HUMANS; ISONIAZID; P-AMINOSALICYLIC ACID; RIFAMPIN; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 0031845967     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Hinshow HC, Feldmann WH : Streptomycin in treatment of clinical tuberculosis : a preliminary report. Proc Staff Meetings Mayo Clin. 1945 ; 20 : 313-318.
2. British Medical Research Council (BMRC) : Treatment of pulmonary tuberculosis with para-amino salicylic acid and streptomycin, preliminary report. Br Med J. 1949 ; 2 : 1521-1525.
3. BMRC : Treatment of pulmonary tuberculosis with streptomycin and para-amino salicylic acid. Brit Med J. 1950 ; 2 : 1073-1085.
4. Ayvazian LF : History of Tuberculosis, Tuberculosis A comprehensive international Approach, Edited by Reichmann LB, Hershfield ES, Marcel Dekker Inc, New York, 1993, 1-20.
5. The Cooperative Study Unit on Chemotherapy of Tuberculosis of The National Sanatoria in Japan : Comparison of PAS, Thioacetazone or 4-4 Diisoamyloxythiocarbanilid with Streptomycin and Isoniazid in previously untreated Patients with Pulmonary Tuberculosis, 1970, 205-214.
6. Sunahara S : Geneticail geographical and clinical studies on isoniazid metabolism. Bull int Union Tuberc. 1962 ; 32 : 513-541.
7. Scottish Thoracic Society : A Study of isoniazid serum levels and their clinical significance in the treatment of pulmonary tuberculosis. Tubercle. 1962; 43 : 139-144.
8. Selken JB, Fox W, Gangadharm PRJ, et al. Rate of inactivation of isoniazid in study of Indian patients with pulmonary tuberculosis. II Clinical implications in the treatment of pulmonary tuberculosis with isoniazid alone or in combination with PAS. Bull Wld Hlth Orga. 1961 ; 25 : 779-792.
9. Tuberculosis Chemotherapy Centre, Madras : A controlled comparison of a twice weekly and once weekly regimens in the initial treatment of pulmonary tuberculosis. Bull Wld Hlth Org. 1970 ; 43 : 143-206.
10. Gangadharam PRJ, Cohen ML, Middlebrook G : Dynamic aspects of the sterilizing action of isoniazid on mycobacterium tuberculosis. Am Rev Resp Dis. 1963 ; 88 : 558-562.
11. Vivien JN, Thibier R, LePeuple T : Recent studies on isoniazid, Advances in Tuberculosis Research, Vol.18 edited by Canett G, S Karger, Basal, 1972, 188-193.
12. Deguchi T, Mashimo M and Suzuki T : Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J Biological Chemistry. 1990 ; 265 : 12757-12760.
13. Parkin DP, Vandenplas S, Botha FJH, et al. : Trimodality of isoniazid elimination, phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997; 155: 1717-1722.
14. Mitchell JR, Thorgeirsson UP, Timbell JA, et al. : Increased incidence of isoniazid hepatitis in rapid acetylators-possible relation to hydrazid metabolism, Clin Pharmacology and Therapeutics. 1975 ; 18 : 70-79.
15. Girling DJ : Adverse effects of antituberculosis drugs. Drugs. 1982 ; 23 : 56-74.
16. Moulding TS : Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis. 1981 ; 264 : 262-264.
17. International against tuberculosis : A comparison of regimens of ethionamide, pyrazinamide and cycloserin in retreatment of patients with pulmonary tuberculosis. Bull int Union Tuberc. 1969 ; 42 : 7-37.
18. Petty TL, Mitchell RS : Successful treatment of advanced isoniazid and streptomycin-resistant pulmonary tuberculosis with ethionamide, pyrazinamide and isoniazid. Amer Rev Respir Dis. 1962 ; 86 : 593-612.
19. Grosset J and Leventis S : Adverse Effects of Rifampin. Reviews of Infectious Dis. 1983 ; 5 supple : 440-446.
20. Zierski M : Adverse reaction under intermittent rifampicin regimens. Chemotherapy. 1976 ; 4 : 385-392.
21. Worlledge S : Rifampicin - induced antibodies. Chemotherapy. 1976 ; 4 : 273-278.
22. Riska N and Matson K : Intermittent rifampicin treatment of tuberculosis, Scand Resp Dis, supple. 1973 ; 84 : 140-144.
23. BMRC : Long term chemotherapy in the treatment of chronic pulmonary tuberculosis with cavitation. A report to the Medical Research Council by their tuberculous chemotherapy trials committee. Tubercle. 1962 ; 43 : 201-267.
24. Cooperative study unit on chemotherapy of tuberculosis of national sanatoria in Japan : Comparison between high daily dosage of isoniazid in divided doses and low daily doses in a single dose in triple drug regimens. Tubercle. 1968 ; 170 : 170-179.
25. Fox W and Mitchison A : State of the Art Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1975 ; 111 : 325-352.
26. Mitchison DA : How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc and Lung Dis. 1998 ; 2 : 10-15.
27. British Thoracic Association : A controlled trial of six-month chemotherapy in pulmonary tuberculosis, second report ; results during the 24months after the end of chemotherapy. Am Rev Respir Dis. 1982 ; 126 : 460-473.
28. Mitchison DA and Dickinson JM : Bactericidal mechanisms in short-course chemotherapy. Bull IUAT. 1978 ; 53 : 254-259.
29. Mitchison DA, Dickinson JM : Laboratory aspects of intermittent drug therapy. Postgrad Med J. 1971 ; 47 : 737-741.
30. Mitchison DA : The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985 ; 80 : 214-225.
31. Jindai A, Edwards EA, Mitchison DA : The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respi Dis. 1980 ; 121 : 939-941.
32. Hirano K, Abe C, Mori T : Resistance to antituberculosis drugs in Japan. Tubercle. 1996 ; 77 : 130-135.
33. Bloch AR, Cauthen GM, Onorato M, et al. : National survey of drug-resistant tuberculosis in the United States. JAMA. 1994 ; 271 : 665-671.
34. Frieden TR, Sterling T, Pubos-Menderz A, et al. : The emergence of drug resistant tuberculosis in the New York city. N Eng J Med : 1993 ; 328 : 521-526.
35. Snider DE, Roper WL : The new tuberculosis, N Eng J Med. 1992 ; 326 : 703-705.
36. Small PM, Shafer RW, Hopwell PC, et al. : Exogenous reinfection with multi-drug-resistant mycobacterium tuberculosis in patients with advanced HIV infection. N Eng J Med. 1993 ; 328 : 1137-1144.
37. Goble M, Iceman MD, Madson LA, et al. : Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Eng J Med. 1993 ; 328 : 527-532.
38. Castro KG and Snider E : Editorial : The good news and the bad news about multidrug-resistant tuberculosis. CID. 1995 ; 2 : 1265-1266.
39. Louni N, Truffot-Pernot C, Grosset J : Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother. 1996 ; 41 : 251-254.
40. Tillotson GS : Tuberculosis-New aspects of chemotherapy. J Med Microbiol, 1996 ; 44 : 16-20.
41. Brogden RN, Filton A : Rifampicin-a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994 ; 47 : 983-1009.
42. Iceman MD : Treatment of multidrug-resistant tuberculosis. New Eng J Med. 1993 ; 329 : 784-791.
43. Dickinson JM, Mitchison DA : in vitro properties of rifampicin (MDL47B) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle. 1987 ; 68 : 113-118.
44. Saito H, Tomioka H, Sato K, et al. : In vitro antimycobacterial activities of newly synthesized Benzoxazinorifamycins. Antimicrobial Agents and Chemother. 1991 ; 35 : 542-547.
45. Sorg TB and Cyamon MH : Comparison of four β-lactamase inhibitors in combination with ampicillin against mycobactrium tuberculosis. J Antimicrobial chemotherapy. 1987 ; 19 : 59-64.
46. Nadler JP, Berger J, Nord JA, et al. : Amoxicillin : clavulamic acid for treating drug-resistant Mycobacterium tuberculosis. Chest. 1991 ; 99 : 1025-1026.
47. Gangadharam PRJ : Gangamicin, a potential antimicobacterial drug, 33rd interscience congress of antimicrobial agents and chemotherapy, 1993.
48. Stanford JL and Stanford CA : Immunotherapy for tuberculosis with M Vacce. J Med Microbiol. 1996 ; 44 : 24-28.
49. Corlan E, Marcia C, Stanford JL, et al. : Immunotherapy with mycobacterium vacce in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease, 1997 ; 91 : 21-29.
50. BMRC : Controlled clinical trial of levamizole in short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1989 ; 140 : 990-995.
51. Conds R, Rom WN, Schluger NW : Treatment of multidrug-resistant pulmonary tuberculosis with interferon- γ via aerosol. Lancet. 1997 ; 349 : 1513-1515.